—

Abingworth LLP

Q4 2022 13F Holdings

  • Location
    london, X0
  • Num holdings

    19

  • Value ($000)

    $306,917

  • Date Filed
    02/10/2023
  • Form type
    13F-HR
  • CIK
    0001397144
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2022 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
P
PCVX

VAXCYTE INC

COM
92243G108
$96.81M
32 %

2,019,057

V
VRNA

VERONA PHARMA PLC

SPONSORED ADS
925050106
$64.21M
21 %

2,457,500

V
VERA

VERA THERAPEUTICS INC

CL A
92337R101
$57.28M
19 %

2,960,231

H
HLVX

HILLEVAX INC

COM
43157M102
$30.76M
10 %

1,838,486

A
ACET

ADICET BIO INC

COM
007002108
$18.91M
6 %

2,115,385

P
PHAT

PHATHOM PHARMACEUTICALS INC

COM
71722W107
$16.1M
5 %

1,435,106

R
RPHM

RENEO PHARMACEUTICALS INC

COM
75974E103
$4.83M
2 %

2,073,957

S
SIEN

SIENTRA INC

COM
82621J105
$3.4M
1 %

1,673,589

J
JSPR

JASPER THERAPEUTICS INC

COM
471871103
$2.72M
1 %

5,628,558

---

SOLENO THERAPEUTICS INC

COM
834203309
$2.38M
1 %

1,201,506

Rows Per Page
10
  • 5
  • 10
  • 20
  • 30
  • 50
  • 100
1 - 10 of 19